Patient Case Studies and Panel Discussion: Leukemia and Myeloproliferative Neoplasms

Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.  As the management of hematologic malignancies has become more complex, the need for education on management decisions has become increasingly necessary.  To provide optimal patient care, clinicians need to be well informed about new and emerging drugs, novel mechanisms of action, and the latest clinical research, and how these advances compare to the current standard of care for patients with hematologic malignancies.  In order to inform decision-making and formulate management strategies for patients with hematologic malignancies, clinicians need up-to-date information and opportunities to apply this information through case-based learning.  Through familiarity with up-to-date guidelines, as well as interpretation and commentary by national experts and discussion with their peers, clinicians can learn to incorporate new treatment strategies and regimens into their oncology practices for the management of patients with hematologic malignancies.

This information was originally presented at the NCCN 13th Annual Congress: Hematologic Malignancies™ held in New York, New York, from September 21-22, 2018.

Target Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Identify clinical challenges in managing patients with leukemia and myeloproliferative neoplasms.
  • Develop an evidence-based approach for the management of these patients.
Additional information

This activity is supported by educational grants from:

  • Astellas
  • AstraZeneca
  • Celgene Corporation
  • Genentech
  • Jazz Pharmaceuticals, Inc.
  • MEI Pharma
  • Novartis
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer
  • Sanofi Genzyme
  • Takeda Oncology

This activity is supported by independent educational grants from AbbVie and Incyte.

This activity is supported by educational funding provided by Amgen.

This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 0.89 ANCC contact hours
  • 1.00 Participation
Course opens: 
Course expires: 

Michael J. Mauro, MD
Memorial Sloan Kettering Cancer Center
Animesh Pardanani, MBBS, PhD
Mayo Clinic Cancer Center

Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
Eunice S. Wang, MD
Roswell Park Comprehensive Cancer Center


Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education (CE) activities are expected to disclose any relevant financial relationships with a commercial interest as defined by ACCME’s, ACPE’s, and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.


NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses no relevant financial relationships:

Animesh Pardanani, MBBS, PhD

The faculty listed below discloses the following relevant financial relationships:

Michael J. Mauro, MD
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee; Grant/Research Support
Pfizer Inc.: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

Jerald P. Radich, MD
Amgen Inc.: Scientific Advisor
Novartis Pharmaceuticals Corporation: Grant/Research Support; Scientific Advisor
Seattle Genetics, Inc.: Scientific Advisor

Eunice S. Wang, MD
AbbVie, Inc.: Scientific Advisor
Amgen Inc.: Consulting Fees, Honoraria
ImmunoGen, Inc.: Grant/Research Support
Incyte Corporation: Product/Speakers Bureau
Novartis Pharmaceuticals Corporation: Product/Speakers Bureau
Otsuka Pharmaceutical Co., Ltd.: Scientific Advisor

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA (employed by NCCN until 8/10/2018); Joan S. McClure, MS (employed by NCCN until 8/1/2018); Lisa Perfidio, MS; Shannon Ryan; Kathy Ann Smith, CMP, CHCP; Gary J. Weyhmuller, MBA, SPHR

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:

Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options

Katherine Pierce
Pfizer Inc.: Equity Interest/Stock Options
Boston Scientific Corporation: Equity Interest/Stock Options

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Mary Anne Bergman; Ndiya Ogba, PhD; Hema Sundar, PhD

National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category 1 credit for completing this activity.

National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 0.89 contact hour.


National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: 0836-0000-18-111-H01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 0.89 ANCC contact hours
  • 1.00 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: